3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 4
2
Phase NA
1
Phase 3
1
Phase 1
1
Status
Completed
3
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Gastro-enteropancreatic neuroendocrine tumor
1
Acromegaly
1
Interventions
Cyclophosphamide
98
pembrolizumab
85
Gemcitabine
81
Carboplatin
62
fludarabine
61
Nivolumab
57
Cisplatin
54
Paclitaxel
51
Radiotherapy
50
Docetaxel
49
Rituximab
46
Dexamethasone
42
Lenalidomide
41
Ipilimumab
38
Azacitidine
35
Etoposide
34
Cytarabine
33
Temozolomide
32
Bevacizumab
32
Radiation
29
venetoclax
28
Bortezomib
27
Magnetic Resonance Spectroscopy
26
Irinotecan
26
Pemetrexed
25
atezolizumab
24
Oxaliplatin
24
Capecitabine
24
fludarabine phosphate
22
Filgrastim
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Terminated
×
Octreotide
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled